Jacqueline Barrientos, MD, MS, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, shares data from the Phase II CAPTIVATE trial (NCT02910583), which investigated the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib and venetoclax in patients with chronic lymphocytic leukemia (CLL). Patients initially received ibrutinib as debulking therapy, and then received 12 cycles of ibrutinib with venetoclax. Complete remission and minimal residual disease (MRD) were observed in a large number of patients, with no changed in toxicity reported. Ibrutinib with venetoclax is a promising regimen that is effective in patient with CLL and can additionally reduce progression rates in patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.